retatrutide switzerland (LY3437943) | GCGR/GLP-1R/GIPR Agonist | CAS 2381089-83-2 Swiss Research

Individuals with chronic health conditions such as autoimmune disorders or chronic fatigue, who may experience improved immune function and reduced inflammation

Your provider can integrate it with other treatments, like our sports injury care or therapeutic bodywork, to support your healing from all angles

Supports Heart Health: Ingredients like CoQ10, Lycopene, and L-Arginine promote cardiovascular health by improving blood flow and reducing oxidative stress

As of September 2023 it is on the FDA Category 2 list of bulk drug substances that may not be compounded, and a PCAC review is scheduled for July 2026 under the name Emideltide